Minerva is the first and only company to generate human stem cells in the earliest “naïve” state. We have identified a novel human growth factor that is present only in the first few days of an embryo and is then turned off for the rest of life. Because these early stem cells are free of cell fate decision marks they are easier to direct to differentiate into mature functional cells of higher quality and functionality than are available by traditional methods. Our system has stable karyotype, no spontaneous differentiation, higher yields, and works with both ES and iPS cells. This will facilitate regenerative therapies of the highest quality, manufacturability, and potency.